Potential Tobacco-Based Vaccine Could Rival Egg-Based Vaccines
- By BSTQ Staff
A new tobacco-based seasonal influenza vaccine being developed by Mitsubishi Tanabe Pharma and currently in Phase III studies could potentially rival traditional chicken egg-based vaccines. The new vaccine, which the company aims to launch in the U.S. for the 2018-19 flu season, uses technology that implants influenza genetic material into tobacco leaves, a method that can produce the vaccine in four weeks, which is six times faster than egg-based methods.
References
- New Tobacco-Based Flu Vaccine Offers Promising Alternative to Egg-Based Versions, Says GlobalData Analyst. Manufacturing Chemist Pharma, March 11, 2016. Accessed at www.manufacturingchemist.com/news/article_page/New_tobaccobased_flu_vaccine_offers_promising_alternative_to_eggbased_versions_says_GlobalData_analyst/116474.
